Journal for Immunotherapy of Cancer

Article	Citations
Author response to comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer	327
Response to "NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng	181
Zelig Eshhar (1941–2025): a tribute for a life for immunotherapy	161
Clinical value of tumor mutational burden for neoadjuvant and adjuvant immune checkpoint inhibitor in early-stage non-small cell lung cancer	155
Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models	152
Constructing a pancancer ubiquitination regulatory network to determine tumor characteristics, immunotherapy response, and prognosis	144
Correction: PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling	140
Correction: Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models	131
Correction: Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer	127
Correction: Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade	126
Correction: influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors	126
Commentary on oncolytic viruses: past, present, and future	125
Clinical trial landscape of CAR-based cell therapy for gastrointestinal malignancies	117
Novel circulating microRNA signature for early detection and prognostication of checkpoint inhibitor-related pneumonitis	114
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells	108
Serotonin transporter SERT: a novel immune checkpoint for CD8 + T cell antitumor therapy	107
Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors	106
Novel CAR T cell blend targeting PDPN and GD2 to overcome glioblastoma heterogeneity	105
Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines	102
Is immunotherapy safe and effective in patients with VEXAS syndrome?	101
Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation	99
TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells	98
Differential phagocytosis induces diverse macrophage activation states in malignant gliomas	97
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma	97
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047	97

Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunothera	96
Evaluation of immune checkpoint inhibitor efficacy for solid tumors with CD274 (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwid	92
Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis	91
B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells	89
Engineering macrophages for effective and safe targeting of CD47 cancer cells in the tumor microenvironment	89
Galectin-9-driven immune evasion constrains radiotherapy-induced systemic antitumor immunity	88
Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis	86
T-cell tolerant fraction as a predictor of immune-related adverse events	86
New insights into the role of IFN-α/β and TLR7/8/9 in cancer immunotherapy and systemic autoimmunity	86
Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer	86
Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study	85
Single-cell analysis reveals clonally expanded tumor-associated CD57 + CD8 T cells are enriched in the periphery of patients with metastatic urotheli	84
Oncolytic adenovirus serotype 35 mediated tumor growth suppression via efficient activation of antitumor immunity	83
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma	82
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype	82
TCR sequencing in cancer immunology and immunotherapy: what, when, where, why, and how	82
Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression	81
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors	80
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy	79
Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer	79
Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases	78
Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells	77
MAIT cells promote cancer progression and regulatory T cell accumulation in bladder tumor microenvironment	77
Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion	76
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap	76
Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade	76
Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach	75
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses	75
Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade	75
Biomarkers for response to TIL therapy: a comprehensive review	73
SAMHD1 drives immunosuppression in non-small cell lung cancer by promoting macrophage infiltration and restricting oncolytic adenovirus replication	71
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision	71
Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies	71
Correction: Antitumor strategies targeting macrophages: the importance of considering the differences in differentiation/polarization processes between human and mouse macrophages	70
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors	70
Vaccination generates functional progenitor tumor-specific CD8 T cells and long-term tumor control	70
Correction: Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy	70
Phase 2 trial of pTVG-HP ± pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)	69
Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC	69
Accumulation of T-cell-suppressive PD-L1high extracellular vesicles is associated with GvHD and might impact GvL efficacy	69
Human blood cell transcriptomics unveils dynamic systemic immune modulation along colorectal cancer progression	69
Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms’ tumor 1 (WT1) peptide cocktail-pulsed dendritic cell vaccine	68
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0	68
A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma	67
Cantharidin overcomes IL-2Rα signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species	67
CD155 links tumor immunotype to epithelial-directed precision therapy beyond checkpoint inhibition in cervical cancer	67
Dual regulation of CXCR6 + CD8 + T cells modulates cytotoxic and exhaustion-associated programs du	66
Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-CCL2-mediated immunity	66
Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALL	66
Targeting immunosuppressive macrophages by CSRP2-regulated CCL28 signaling sensitizes hepatocellular carcinoma to lenvatinib	66

Correction: Macrophage sensitivity to bexmarilimab-induced reprogramming is shaped by the tumor microenvironment	65
Systemic STING agonist therapy drives expression of interferon stimulated genes and downstream production of cytokines in dogs with solid tumors	65
Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation study	64
Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer	64
Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination	64
CD33 KO -CD33-mesothelin Loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemia	64
Apoptosis: a Janus bifrons in T-cell immunotherapy	64
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial	63
Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications	62
Sulforaphane activates CD8+ T cells antitumor response through IL-12RB2/MMP3/FasL-induced MDSCs apoptosis’	62
Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment	61
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes	61
TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion	61
Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch	60
In memoriam: Soldano Ferrone, MD, PhD (1940–2023)	60
PD-L1 gene amplification and focality: relationship with protein expression	59
Stress-NRF2 response axis polarizes tumor macrophages and undermines immunotherapy	59
Modulating lipid metabolism improves tumor immunotherapy	58
TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma	58
Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival outcomes and immune-inflammatory profiles in patients with advanced NSCLC undergoing first-line immunotherapy	58
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy	58
RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells	57
PD-1 blockade employed at the time CD8+ T cells are activated enhances their antitumor efficacy	57
Spatial architecture of tertiary lymphoid structures represents an independent prognostic dimension in hepatocellular carcinoma	57
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix	57
Poor clinical outcomes and immunoevasive contexture in CD161+CD8+ T cells barren human pancreatic cancer	57
Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies	56
Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models	56
Irreversible electroporation synergizes with oncolytic virus enhances the infiltration of cytotoxic T lymphocytes in the tumor immune microenvironment: a leap from focal therapy to immunotherapy for p	56
Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition	55
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D	55
Novel post-translational modification learning signature reveals B4GALT2 as an immune exclusion regulator in lung adenocarcinoma	55
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16	54
Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function	54
Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials	54
SIGLEC11 promotes M2 macrophage polarization through AKT–mTOR signaling and facilitates the progression of gastric cancer	54
Tumor-secreted AGR2 induces dendritic cell dysfunction and impairs immunotherapy efficacy in LKB1-deficient cancer	54
Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation	54
Paclitaxel, interferons and functional reprogramming of tumor-associated macrophages in optimized chemo-immunotherapy	53
Combined circulating tumor antigen model demonstrates additional prognostic value in first-line treatment of non-small cell lung cancer	53
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy	53
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs	53
Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechalle	53
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis	53
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma	52
Advancing ICOS agonism in solid tumors: lessons from INDUCE-1	52
Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity	52
Irreversible electroporation augments β-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma	52
Targeting SPP1 + TAMs associated with liver metastasis reverses immunosuppression and synergizes with immunotherapy in col	52
Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity	52
Natural killer cells are required for the recruitment of CD8+ T cells and the efficacy of immune checkpoint blockade in melanoma brain metastases	52
Combination of a novel TCR Vβ chain-directed selective T cell activator with standard of care therapy for head and neck cancer improves antitumor responses and promotes regression of checkpoint-refrac	52
Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma	51
Reinforcing cancer immunotherapy with engineered porous hollow mycobacterium tuberculosis loaded with tumor neoantigens	51
Blocking LIF and PD-L1 enhances the antitumor efficacy of SBRT in murine PDAC models	50
Author response to Zhang et al	50
PD-L1-targeted PET imaging for non-invasive assessment of immunotherapy response in lung cancer	50
Serotonin receptor 5-HT 2A as a potential target for HCC immunotherapy	50
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors	49
Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells	49
Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors	49
Rescuing natural killer cells from the cancer wilderness	49
PLS-α-GalCer: a novel targeted glycolipid therapy for solid tumors	48
Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy	48
Correction: Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody	48
Correction: Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events	48
Exploring molecular imaging to investigate immune checkpoint inhibitor-related toxicity	48
Corticosteroid premedication on anti-tumor effect of immune checkpoint blockade in murine hepatocellular carcinoma models	48
Integrated single-cell transcriptome and TCR profiles of hepatocellular carcinoma highlight the convergence on interferon signaling during immunotherapy	47
Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al	47
Correction: Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers	47
Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors	47
Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization	47
Correction: Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel	47
Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors	47
Correction: Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma	47
Id-neoantigen vaccine induces therapeutic CD8+ T cells against multiple myeloma: H chain-loss escapees cause FLC MM	46
Anti-CTGF/PD-1 bispecific antibody Y126S restrains desmoplastic and immunosuppressive microenvironment in pancreatic cancer	46
Spatial immune remodeling of the liver metastases: discovering the path to antimetastatic therapy	46
Guidelines for immunological analyses following focused ultrasound treatment	46

Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentical hematopoietic stem cell transplantation	46
Gut microbiome-depleting antibiotic regimens are not tolerated by all mouse strains: learn from (our) bitter experience	46
Immune-modulating effects on tumor-draining lymph nodes of neoadjuvant chemoradiotherapy combined with dual immunotherapy in patients with T3-4N0-2 NSCLC	46
Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report	46
Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a ph	45
Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study)	45
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms	45
Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses	45
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders	45
Peritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity	45
Oncolytic virus OH2 induces PD-L1 upregulation via NF-κB signaling and synergizes with anti-PD-L1 therapy in prostate cancer through a targeted extracellular vesicle delivery system	45
Potentiation of cancer immunogenicity by targeting PARP	45
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial	44
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG	44
Allele-specific HLA LOH in solid tumors: distinct patterns by tumor type and potential prognostic relevance	44
Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma	44
Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer	44
Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer	43
HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity	43
Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity?	43
Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis	43
Induction toripalimab plus chemotherapy sequential concurrent chemoradiotherapy with nimotuzumab followed by toripalimab maintenance in stage IVB hypopharyngeal squamous cell carcinoma: a single-arm p	43
Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy	43
Novel oncolytic adenovirus-based PEPvIII vaccine displays a super antitumor effect in glioma models	43
Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade	43
Correction: MRI techniques for immunotherapy monitoring	42
Salmonella-mediated methionine deprivation drives immune activation and enhances immune checkpoint blockade therapy in melanoma	42
Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation	42
Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer	42
Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer	41
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive	41
Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy	41
Correction: Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy	41
Clinical-radiomics nomogram integrating lymph node radiomic features to predict immunotherapy response in advanced biliary tract cancers	41
Novel treatments for novel side effects: a case report and review of baricitinib use in the treatment of chronic inflammatory demyelinating polyneuropathy caused by immune checkpoint inhibitor use	41
Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors	41
Polymorphonuclear myeloid-derived suppressor cells and phosphatidylinositol-3 kinase gamma are critical to tobacco-mimicking oral carcinogenesis in mice	41
Letter to the editor: transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study	41
Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR	41
Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial	41
Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C	41
Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?	41
Comment on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’	41
Selective BCL-2 inhibitor triggers STING-dependent antitumor immunity via inducing mtDNA release	40
Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment	40
NK cells link immune-checkpoint blockade immunotherapy and response in melanoma brain metastases	40
Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma	40
Emergence of a mixed CAF population by FAP-CD3 T-cell engager limits therapeutic efficacy	40
Paired single-B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cells in acute myeloid leukemia	40
Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma	40
Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancer	40
Disruption of cell-intrinsic PCSK9 enhances the antitumor efficacy of CD8 + T cells	40
Body mass index and type 2 diabetes mellitus as metabolic determinants of immune checkpoint inhibitors response in melanoma	40
Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma	40
ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers	40
CD56bright cytokine-induced memory-like NK cells and NK-cell engagers synergize against non-small cell lung cancer cancer-stem cells	40
Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-α triggers tumorigenic inflammation in neuroblastoma	40
Inhibition of osteosarcoma lung metastases by β-glucan and CD40 agonist is mediated by activation of macrophages and NK cells	40
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab	39
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis	39
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells	39
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas	39
Spatial TCR clonality and clonal expansion in the in situ microenvironment of non-small cell lung cancer	39
Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy	39
TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma	39
Specific inhibitor to KRASG12C induces tumor-specific immunity and synergizes with oncolytic virus for enhanced cancer immunotherapy	39
AGPAT3 reshapes tumor cell vulnerability to IFNγ-mediated ferroptosis and enhances immunotherapy efficacy through lipid remodeling	38
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817	38
LysoPS-GPR34 axis enhances tumor-associated macrophages efferocytosis to promote immune escape in gastric cancer peritoneal metastasis	38
Constructing the cure: engineering the next wave of antibody and cellular immune therapies	38
Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer	38
Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase	38
In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade	38
Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies	38
HOXD13-mediated immune crosstalk between cancer cells and tumor-associated macrophages drives colorectal cancer progression	38
Assessment and predictive ability of the absolute neutrophil count in peripheral blood for in vivo CAR T cells expansion and CRS	38
Programmed death-1 inhibition increases vaccine-induced T-cell infiltration in patients with prostate cancer	38
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types	37
Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses	37
No detrimental association between antibiotic use and immune checkpoint inhibitor therapy: an observational cohort study comparing patients with ICI-treated and TKI-treated melanoma and NSCLC	37
Mapping the TCR landscape: computational tools empowering translational immunology and therapy design	37
Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY tria	37
Therapeutic inhibition of USP7 promotes antitumor immune responses	37
Multiomics profiling reveals the benefits of gamma-delta (γδ) T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancer	37
Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin	37
Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective study	37
Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response	36
HSP47 inhibition-induced CD155 expression through TRAF2 deubiquitination promotes tumor immune evasion	36
Cytokine storm complicated by cardiogenic shock induced by anti-HER2 therapies	36
Correction: Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8+ TILs based on BRCA1/2 mutation status in epithelial ovarian cancers	36
Targeting the novel immune checkpoint KLRG1 is markedly therapeutic against cancer through multiple lymphocyte subsets	36
TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy	36
MCT4 blockade increases the efficacy of immune checkpoint blockade	36
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)	36
Association of 5α-reductase inhibitor prescription with immunotherapy efficacy in metastatic renal cell carcinoma: a multicenter retrospective analysis	36